Truist Securities Reiterates Buy on Viking Therapeutics, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has reiterated a 'Buy' rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $32.
October 02, 2023 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics has received a reiterated 'Buy' rating from Truist Securities, with a maintained price target of $32.
The reiterated 'Buy' rating and maintained price target by Truist Securities indicates a positive outlook for Viking Therapeutics. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100